z-logo
Premium
Individual Difference in the Pharmacokinetics of a Drug, Pravastatin, in Healthy Subjects
Author(s) -
Ogawa Katsutoshi,
Hasegawa Setsuo,
Udaka Yuko,
Nara Keinosuke,
Iwai Shinichi,
Oguchi Katsuji
Publication year - 2003
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270003257232
Subject(s) - pravastatin , cmax , pharmacokinetics , outlier , medicine , pharmacology , mathematics , statistics , cholesterol
The purpose of this investigation was to determine whether there were individual pharmacokinetic differences of a drug, pravastatin. Furthermore, the percentage of subjects who showed pharmacokinetic differences was determined. A single oral dose of pravastatin 10 mg was administered to 84 Japanese healthy male subjects. Serum concentrations of pravastatin were measured for 8 hours postdose. Area under the concentration‐time curve (AUC) and peak concentration (C max ) were determined as primary evaluation parameters. An outlier was defined as follows: Outlier 1 < Q1 ‐ (Q3 ‐ Q1) × 1.5 or Q3 + (Q3 ‐ Q1) × 1.5 < Outlier 1, Outlier 2 < Q1 ‐ (Q3 ‐ Q1) × 3 or Q3 + (Q3 ‐ Q1) × 3 < Outlier 2. Subjects who were outliers were regarded as having an individual difference in pharmacokinetic behavior. In AUC and C max , 4 of 84 subjects (4.8%) were higher outliers. Of these 4 subjects, 2 were high outliers in both AUC and C max . No subjects were low outliers. It was concluded that a significant individual difference in the pharmacokinetics of pravastatin was observed in 4.8% of the subjects (4/84) .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom